Tumor Metabolome Targeting and Drug Development - Couverture rigide

Livre 79 sur 96: Cancer Drug Discovery and Development

Kanner

 
9781461495444: Tumor Metabolome Targeting and Drug Development

Synopsis

Chapter 1: Tumor cell metabolic reprogramming and drug targeting (Steven B. Kanner)
Chapter 2: Cancer metabolism: a nexus of matter, energy and reactive oxygen species (Paul M. Bingham, Shawn D. Stuart, Zuzana Zachar) Chapter 3: Regulating mitochondrial respiration in cancer (Teresa L. Serafim and Paulo J. Oliveira)
Chapter 4: Regulation of cancer cell metabolism by hypoxia (Ashleigh Pulkoski-Gross, Nikki A. Evensen and Jian Cao)
Chapter 5: Glucose metabolism and the anti-oxidative defence system in cancer cells: Options for application of ROS-based anticancer drugs (Gernot Bruchelt, Rupert Handgretinger, Mirjam Weckenmann, Talia Hahn)
Chapter 6: Modulating autophagy and the "reverse Warburg effect" (Maria Vaccaro, Claudio D. Gonzalez, Silvia Alvarez and Alejandro Ropolo)
Chapter 7: Metabolic adaptation in reprogrammed cancer cells (Kevin Marks and Charles Kung)
Chapter 8: Targeting of PFKFB3 (Katarina Färnegårdh, Maria Shoshan, Lars Ährlund-Richter)

Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.

À propos de l'auteur

Dr. Steven B. Kanner is the Vice President of Discovery Biology at Astex Pharmaceuticals. He has been a pharmaceutical research leader with over 20 years of extensive experience in novel target identification and validation, assay development, both small molecule and antibody drug discovery, and expertise in oncology, immunology and inflammation. For more detail, please see the attached CV herewith.

Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.

Autres éditions populaires du même titre